Haleon, the consumer healthcare company behind brands like Sensodyne and Centrum, saw its stock price plummet 5.05% in intraday trading on Thursday. This sharp decline came after the company's revenue growth forecast for 2025 fell short of analysts' expectations.
According to Haleon's guidance, the company expects organic revenue growth of 4% to 6% for the year 2025, lower than the consensus estimate of 5.3%. While the company reported solid fourth-quarter results and full-year revenue of £11.23 billion, in line with expectations, investors seemed concerned about the potential slowdown in growth.
Analysts at Jefferies acknowledged the strong fourth-quarter sales but noted that the company's "broad outlook commitment" overshadowed these positive results. They described Haleon's forecast as "wise" given the ongoing uncertainties, but it appears that the market had higher expectations for the company's revenue growth trajectory.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。